BidaskClub downgraded shares of Nektar Therapeutics (NASDAQ:NKTR) from a buy rating to a hold rating in a research report sent to investors on Tuesday, September 18th.

Several other equities research analysts also recently weighed in on NKTR. ValuEngine downgraded shares of Nektar Therapeutics from a buy rating to a hold rating in a report on Tuesday, June 26th. Zacks Investment Research upgraded Nektar Therapeutics from a hold rating to a buy rating and set a $54.00 target price on the stock in a report on Monday, July 16th. HC Wainwright set a $54.00 price objective on Nektar Therapeutics and gave the stock a hold rating in a report on Friday, August 10th. TheStreet upgraded Nektar Therapeutics from a d rating to a c rating in a report on Wednesday, August 8th. Finally, William Blair restated a buy rating on shares of Nektar Therapeutics in a report on Monday, June 4th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $82.91.

Shares of NASDAQ NKTR traded up $1.01 during trading on Tuesday, reaching $48.91. 2,001,546 shares of the stock were exchanged, compared to its average volume of 3,167,571. The stock has a market cap of $10.51 billion, a P/E ratio of -88.93 and a beta of 2.39. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13. Nektar Therapeutics has a twelve month low of $22.75 and a twelve month high of $111.36.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.11. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The firm’s revenue for the quarter was up 3043.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.39) earnings per share. On average, research analysts expect that Nektar Therapeutics will post 3.77 EPS for the current fiscal year.

In other Nektar Therapeutics news, Director Dennis L. Winger sold 30,000 shares of the stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $59.96, for a total transaction of $1,798,800.00. Following the completion of the transaction, the director now directly owns 57,750 shares in the company, valued at $3,462,690. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis L. Winger sold 34,250 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now owns 59,875 shares of the company’s stock, valued at $3,628,425. The disclosure for this sale can be found here. Insiders have sold 96,000 shares of company stock valued at $5,825,680 over the last quarter. Corporate insiders own 4.31% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Asset Management One Co. Ltd. bought a new position in Nektar Therapeutics during the first quarter worth about $110,000. We Are One Seven LLC bought a new position in Nektar Therapeutics during the first quarter worth about $118,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in Nektar Therapeutics during the second quarter worth about $137,000. Flagship Harbor Advisors LLC bought a new position in Nektar Therapeutics during the second quarter worth about $142,000. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in Nektar Therapeutics by 68.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 4,290 shares of the biopharmaceutical company’s stock worth $209,000 after buying an additional 1,747 shares during the last quarter. Hedge funds and other institutional investors own 92.20% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Read More: What is Compound Annual Growth Rate (CAGR)?

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.